Buyers must provide the generic drug name (INN), exact dosage form (tablet, syrup, inhaler), active ingredient strength, packing specifications, target order volume, and required regulatory certificates (such as GMP or CPP).
Category market report
Respiratory System Drugs
Total suppliers
6,890+
Total Chinese suppliers export
$9.5B+
Recommended
High-quality suppliers related to Respiratory System Drugs.
Suppliers
Find more suppliers who may be worth contacting.
Top suppliers
Suppliers in this category.
- Transactions
1,897
2018-012022-032026-08Transaction trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 4
- 2018-02: 2
- 2018-03: 3
- 2018-04: 4
- 2018-05: 3
- 2018-06: 10
- 2018-07: 5
- 2018-09: 10
- 2018-10: 2
- 2018-11: 1
- 2018-12: 1
- 2019-01: 32
- 2019-02: 19
- 2019-03: 17
- 2019-04: 13
- 2019-05: 19
- 2019-06: 16
- 2019-07: 9
- 2019-08: 5
- 2019-09: 4
- 2019-10: 7
- 2019-11: 13
- 2019-12: 15
- 2020-01: 24
- 2020-02: 1
- 2020-03: 18
- 2020-04: 30
- 2020-05: 27
- 2020-06: 14
- 2020-07: 13
- 2020-08: 38
- 2020-09: 4
- 2020-10: 21
- 2020-11: 28
- 2020-12: 16
- 2021-01: 9
- 2021-02: 42
- 2021-03: 23
- 2021-04: 20
- 2021-05: 44
- 2021-06: 23
- 2021-07: 19
- 2021-08: 33
- 2021-09: 15
- 2021-10: 46
- 2021-11: 27
- 2021-12: 22
- 2022-01: 43
- 2022-02: 9
- 2022-03: 22
- 2022-04: 30
- 2022-05: 24
- 2022-06: 26
- 2022-07: 19
- 2022-08: 18
- 2022-09: 19
- 2022-10: 34
- 2022-11: 12
- 2022-12: 37
- 2023-01: 13
- 2023-02: 19
- 2023-03: 51
- 2023-04: 22
- 2023-05: 12
- 2023-06: 26
- 2023-07: 23
- 2023-08: 17
- 2023-09: 45
- 2023-10: 10
- 2023-11: 32
- 2023-12: 15
- 2024-02: 28
- 2024-03: 12
- 2024-05: 31
- 2024-06: 18
- 2024-07: 16
- 2024-08: 6
- 2024-09: 15
- 2024-10: 16
- 2024-11: 11
- 2024-12: 14
- 2025-01: 21
- 2025-02: 14
- 2025-03: 19
- 2025-04: 13
- 2025-05: 9
- 2025-06: 11
- 2025-07: 20
- 2025-08: 17
- 2025-09: 13
- 2025-10: 7
- 2025-11: 13
- 2025-12: 16
- 2026-01: 21
- 2026-03: 13
- 2026-04: 49
- 2026-05: 34
- 2026-06: 28
- 2026-07: 28
- 2026-08: 14
- Amount
4,100,621.13
2018-012022-032026-08Amount trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 19.5M
- 2018-02: 23.3K
- 2018-03: 613.5K
- 2018-04: 401K
- 2018-05: 53.6K
- 2018-06: 195.8K
- 2018-07: 174.2K
- 2018-09: 1.4M
- 2018-10: 143.4K
- 2018-11: 27.6K
- 2018-12: 23K
- 2019-01: 40.7B
- 2019-02: 2.8M
- 2019-03: 2.4M
- 2019-04: 1.7M
- 2019-05: 2.6M
- 2019-06: 3.1M
- 2019-07: 1.8M
- 2019-08: 840.4K
- 2019-09: 772.1K
- 2019-10: 2.5M
- 2019-11: 2M
- 2019-12: 1.8M
- 2020-01: 7M
- 2020-02: 9,942.19
- 2020-03: 3.1M
- 2020-04: 4.1M
- 2020-05: 4.5M
- 2020-06: 5.9M
- 2020-07: 2.1M
- 2020-08: 7.6M
- 2020-09: 281.4K
- 2020-10: 1.8M
- 2020-11: 2.3M
- 2020-12: 2.1M
- 2021-01: 927.7K
- 2021-02: 5.9M
- 2021-03: 3M
- 2021-04: 2.8M
- 2021-05: 6.3M
- 2021-06: 4.1M
- 2021-07: 2.5M
- 2021-08: 4M
- 2021-09: 3.4M
- 2021-10: 7M
- 2021-11: 3.9M
- 2021-12: 4M
- 2022-01: 8.5M
- 2022-02: 2.3M
- 2022-03: 2.2M
- 2022-04: 5.2M
- 2022-05: 2.8M
- 2022-06: 4.1M
- 2022-07: 3.3M
- 2022-08: 2.1M
- 2022-09: 2.8M
- 2022-10: 5.3M
- 2022-11: 2M
- 2022-12: 5.9M
- 2023-01: 1.2M
- 2023-02: 3.3M
- 2023-03: 6.5M
- 2023-04: 3.4M
- 2023-05: 3.1M
- 2023-06: 3.4M
- 2023-07: 2.5M
- 2023-08: 2.8M
- 2023-09: 6.7M
- 2023-10: 1.9M
- 2023-11: 5.4M
- 2023-12: 3.1M
- 2024-02: 8.1M
- 2024-03: 3.1M
- 2024-05: 5.5M
- 2024-06: 3.3M
- 2024-07: 3M
- 2024-08: 1.3M
- 2024-09: 2.5M
- 2024-10: 2.2M
- 2024-11: 2M
- 2024-12: 1.8M
- 2025-01: 4.7M
- 2025-02: 1M
- 2025-03: 2.5M
- 2025-04: 2.9M
- 2025-05: 2.5M
- 2025-06: 1.9M
- 2025-07: 3M
- 2025-08: 1.3M
- 2025-09: 2.8M
- 2025-10: 661.9K
- 2025-11: 2M
- 2025-12: 3.1M
- 2026-01: 1.9M
- 2026-03: 697.5K
- 2026-04: 3.1M
- 2026-05: 1.7M
- 2026-06: 1.4M
- 2026-07: 799.3K
- 2026-08: 117.8K
- Main export countries
- India (0.6%)
- Sri Lanka (0%)
- Namibia (0%)
- Mexico (99.3%)
- Transactions
47
2019-012020-102021-09Transaction trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 32
- 2019-11: 2
- 2020-04: 2
- 2020-05: 1
- 2020-06: 1
- 2020-10: 1
- 2021-03: 2
- 2021-04: 1
- 2021-05: 1
- 2021-07: 1
- 2021-08: 1
- 2021-09: 2
- Amount
559,462.81
2019-012020-102021-09Amount trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 5.6B
- 2019-11: 24.9K
- 2020-04: 22.1K
- 2020-05: 11.8K
- 2020-06: 12.3K
- 2020-10: 11.9K
- 2021-03: 24.6K
- 2021-04: 12.5K
- 2021-05: 12.7K
- 2021-07: 12.5K
- 2021-08: 12.5K
- 2021-09: 25.3K
- Main export countries
- Indonesia (100%)
- Transactions
2,150
2018-012022-072026-09Transaction trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 9
- 2018-02: 12
- 2018-03: 11
- 2018-04: 7
- 2018-05: 11
- 2018-06: 19
- 2018-07: 14
- 2018-08: 21
- 2018-09: 20
- 2018-10: 15
- 2018-11: 15
- 2018-12: 10
- 2019-01: 21
- 2019-02: 4
- 2019-03: 10
- 2019-04: 12
- 2019-05: 19
- 2019-06: 9
- 2019-07: 7
- 2019-08: 17
- 2019-09: 14
- 2019-10: 9
- 2019-11: 22
- 2019-12: 14
- 2020-01: 14
- 2020-02: 16
- 2020-03: 5
- 2020-05: 6
- 2020-06: 22
- 2020-08: 18
- 2020-10: 20
- 2020-11: 21
- 2020-12: 8
- 2021-02: 8
- 2021-03: 19
- 2021-04: 10
- 2021-05: 15
- 2021-06: 9
- 2021-07: 16
- 2021-08: 11
- 2021-09: 8
- 2021-10: 18
- 2021-11: 20
- 2021-12: 28
- 2022-01: 12
- 2022-02: 18
- 2022-03: 19
- 2022-05: 17
- 2022-06: 19
- 2022-07: 25
- 2022-08: 15
- 2022-09: 41
- 2022-10: 25
- 2022-11: 28
- 2022-12: 38
- 2023-01: 30
- 2023-02: 11
- 2023-03: 43
- 2023-04: 42
- 2023-05: 29
- 2023-06: 18
- 2023-07: 25
- 2023-08: 19
- 2023-09: 15
- 2023-10: 27
- 2023-11: 24
- 2023-12: 20
- 2024-01: 44
- 2024-02: 34
- 2024-03: 21
- 2024-04: 37
- 2024-05: 32
- 2024-06: 19
- 2024-07: 16
- 2024-08: 14
- 2024-09: 21
- 2024-10: 35
- 2024-11: 44
- 2024-12: 56
- 2025-01: 39
- 2025-02: 43
- 2025-03: 41
- 2025-04: 28
- 2025-05: 31
- 2025-06: 21
- 2025-07: 32
- 2025-08: 13
- 2025-09: 16
- 2025-10: 20
- 2025-11: 15
- 2025-12: 16
- 2026-01: 24
- 2026-02: 22
- 2026-03: 30
- 2026-04: 23
- 2026-05: 37
- 2026-06: 46
- 2026-07: 14
- 2026-08: 14
- 2026-09: 24
- Amount
82,855.66
2018-012022-072026-09Amount trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 3.5M
- 2018-02: 4.8M
- 2018-03: 4.8M
- 2018-04: 1.9M
- 2018-05: 2M
- 2018-06: 5.1M
- 2018-07: 2.9M
- 2018-08: 5.5M
- 2018-09: 5.5M
- 2018-10: 4.2M
- 2018-11: 7.5M
- 2018-12: 2.4M
- 2019-01: 6.4M
- 2019-02: 1.4M
- 2019-03: 5.2M
- 2019-04: 4.2M
- 2019-05: 5.2M
- 2019-06: 3M
- 2019-07: 2.3M
- 2019-08: 5M
- 2019-09: 4.6M
- 2019-10: 3.7M
- 2019-11: 6.6M
- 2019-12: 2.5M
- 2020-01: 3.7M
- 2020-02: 5.3M
- 2020-03: 1.8M
- 2020-05: 1.9M
- 2020-06: 12.1M
- 2020-08: 5.9M
- 2020-10: 10.2M
- 2020-11: 13M
- 2020-12: 4.8M
- 2021-02: 2.9M
- 2021-03: 11.4M
- 2021-04: 4.8M
- 2021-05: 6M
- 2021-06: 5.5M
- 2021-07: 8.9M
- 2021-08: 7.6M
- 2021-09: 3.1M
- 2021-10: 9.9M
- 2021-11: 11.6M
- 2021-12: 13.5M
- 2022-01: 7.1M
- 2022-02: 12.3M
- 2022-03: 9.4M
- 2022-05: 8.1M
- 2022-06: 14.3M
- 2022-07: 16.1M
- 2022-08: 6.7M
- 2022-09: 15.5M
- 2022-10: 10.7M
- 2022-11: 12.3M
- 2022-12: 36.8M
- 2023-01: 13.5M
- 2023-02: 5.4M
- 2023-03: 17.7M
- 2023-04: 21M
- 2023-05: 11M
- 2023-06: 11.2M
- 2023-07: 9.1M
- 2023-08: 8.5M
- 2023-09: 6.3M
- 2023-10: 9.8M
- 2023-11: 9.2M
- 2023-12: 7.8M
- 2024-01: 16.7M
- 2024-02: 13.6M
- 2024-03: 6.9M
- 2024-04: 11M
- 2024-05: 10.4M
- 2024-06: 7.2M
- 2024-07: 9.3M
- 2024-08: 6.6M
- 2024-09: 5.2M
- 2024-10: 11.5M
- 2024-11: 10.1M
- 2024-12: 12.5M
- 2025-01: 10.9M
- 2025-02: 9.8M
- 2025-03: 7.5M
- 2025-04: 4.7M
- 2025-05: 7.4M
- 2025-06: 4.7M
- 2025-07: 12.4M
- 2025-08: 3.5M
- 2025-09: 5.5M
- 2025-10: 5.4M
- 2025-11: 3.7M
- 2025-12: 4.2M
- 2026-01: 6.1M
- 2026-02: 6.3M
- 2026-03: 8.5M
- 2026-04: 6.3M
- 2026-05: 16.2M
- 2026-06: 13.9M
- 2026-07: 3.7M
- 2026-08: 4.2M
- 2026-09: 6.8M
- Main export countries
- United States (99.1%)
- India (0%)
- Not available (0.9%)
Intelligence
China export momentum, destination markets, and regional demand.
China export trend
China export trend
- Date 2018-07: Value 3.1B USD
- Date 2018-08: Value 3B USD
- Date 2018-09: Value 2.7B USD
- Date 2018-10: Value 2.8B USD
- Date 2018-11: Value 3.4B USD
- Date 2018-12: Value 3.3B USD
- Date 2019-01: Value 3.3B USD
- Date 2019-02: Value 2.1B USD
- Date 2019-03: Value 3.4B USD
- Date 2019-04: Value 3.7B USD
- Date 2019-05: Value 4B USD
- Date 2019-06: Value 3.4B USD
- Date 2019-07: Value 3.7B USD
- Date 2019-08: Value 3.7B USD
- Date 2019-09: Value 3.5B USD
- Date 2019-10: Value 3.7B USD
- Date 2019-11: Value 4.2B USD
- Date 2019-12: Value 4.2B USD
- Date 2020-01: Value 0 USD
- Date 2020-02: Value 6.1B USD
- Date 2020-03: Value 4.6B USD
- Date 2020-04: Value 4.3B USD
- Date 2020-05: Value 3.5B USD
- Date 2020-06: Value 0 USD
- Date 2020-07: Value 0 USD
- Date 2020-08: Value 0 USD
- Date 2020-09: Value 4.1B USD
- Date 2020-10: Value 3B USD
- Date 2020-11: Value 3.5B USD
- Date 2020-12: Value 3.1B USD
- Date 2021-01: Value 205M USD
- Date 2021-02: Value 171M USD
- Date 2021-03: Value 204M USD
- Date 2021-04: Value 227M USD
- Date 2021-05: Value 194M USD
- Date 2021-06: Value 199M USD
- Date 2021-07: Value 219M USD
- Date 2021-08: Value 193M USD
- Date 2021-09: Value 229M USD
- Date 2021-10: Value 232M USD
- Date 2021-11: Value 227M USD
- Date 2021-12: Value 251M USD
- Date 2022-01: Value 254M USD
- Date 2022-02: Value 184M USD
- Date 2022-03: Value 270M USD
- Date 2022-04: Value 223M USD
- Date 2022-05: Value 241M USD
- Date 2022-06: Value 221M USD
- Date 2022-07: Value 239M USD
- Date 2022-08: Value 235M USD
- Date 2022-09: Value 229M USD
- Date 2022-10: Value 200M USD
- Date 2022-11: Value 253M USD
- Date 2022-12: Value 217M USD
- Date 2023-01: Value 199M USD
- Date 2023-02: Value 185M USD
- Date 2023-03: Value 227M USD
- Date 2023-04: Value 213M USD
- Date 2023-05: Value 246M USD
- Date 2023-06: Value 240M USD
- Date 2023-07: Value 191M USD
- Date 2023-08: Value 229M USD
- Date 2023-09: Value 240M USD
- Date 2023-10: Value 176M USD
- Date 2023-11: Value 220M USD
- Date 2023-12: Value 246M USD
- Date 2024-01: Value 318M USD
- Date 2024-02: Value 207M USD
- Date 2024-03: Value 288M USD
- Date 2024-04: Value 259M USD
- Date 2024-05: Value 223M USD
- Date 2024-06: Value 304M USD
- Date 2024-07: Value 269M USD
- Date 2024-08: Value 285M USD
- Date 2024-09: Value 277M USD
- Date 2024-10: Value 255M USD
- Date 2024-11: Value 298M USD
- Date 2024-12: Value 357M USD
- Date 2025-01: Value 320M USD
- Date 2025-02: Value 223M USD
- Date 2025-03: Value 304M USD
- Date 2025-04: Value 298M USD
- Date 2025-05: Value 296M USD
- Date 2025-06: Value 296M USD
- Date 2025-07: Value 319M USD
- Date 2025-08: Value 304M USD
- Date 2025-09: Value 305M USD
- Date 2025-10: Value 210M USD
- Date 2025-11: Value 322M USD
- Date 2025-12: Value 325M USD
- Date 2026-01: Value 336M USD
- Date 2026-02: Value 246M USD
- Date 2026-03: Value 298M USD
- Date 2026-04: Value 319M USD
- Date 2026-05: Value 295M USD
- Date 2026-06: Value 368M USD
- Date 2026-07: Value 348M USD
Top destinations
- Germany22.7B
- United States10.9B
- France8.3B
- Sweden8B
- Italy7.4B
- Australia6.6B
- United Kingdom5.7B
- Japan3.9B
- Switzerland3.3B
- Puerto Rico2.7B
Top destinations
- Germany: 22,668,000,000 USD
- United States: 10,930,000,000 USD
- France: 8,287,000,000 USD
- Sweden: 7,990,000,000 USD
- Italy: 7,364,000,000 USD
- Australia: 6,588,000,000 USD
- United Kingdom: 5,749,000,000 USD
- Japan: 3,902,000,000 USD
- Switzerland: 3,268,000,000 USD
- Puerto Rico: 2,732,000,000 USD
Key findings
Largest import market
22.67B USD
Germany · last 8 years
Fastest demand growth
56,399.16
Montenegro · last 8 years
Highest unit price
$1,668.19 /kg
United Kingdom · +1,785.5% vs avg
Turn this market into qualified conversations.
Your agent contacts, compares, and screens the suppliers that fit.
Insights
Product insights to guide your sourcing.
Product Trends
Dry powder inhalers and nasal spray formulations show strong export demand due to rising global asthma and COPD treatments. Combined active ingredient formulations and portable drug-device integrated systems represent key incremental market opportunities.
Industrial Cluster Analysis
The Yangtze River Delta (Jiangsu, Zhejiang) specializes in high-barrier sterile formulations under international GMP standards. Hebei (Shijiazhuang) provides large-scale, cost-effective chemical tablets and syrups.
Quality Expectations
Buyers expect strict compliance with international GMP (such as EU GMP or PIC/S). Inhaled drugs must maintain precise aerodynamic particle size distribution, dose uniformity, and sterile container-closure integrity.
What You Need to Know
Buyers should request the GMP certificates, Certificate of Analysis (COA) of recent batches, and stability study reports. Small-batch registration samples should be imported for lab testing and local registration verification.
MOQ ranges from 10,000 to 50,000 packs depending on the packaging. Production lead time usually takes 60 to 90 days, which excludes the additional time required for local customs clearance and international transport.
Buyers should budget for international freight, import duties, local pharmaceutical registration fees, bioequivalence or lab testing costs, and specialized temperature-controlled packaging and cold-chain shipping.
